-
- Guadalupe Aparicio-Gallego
- Authors' Affiliations: 1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña; 2Clinical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
-
- Moisés Blanco
- Authors' Affiliations: 1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña; 2Clinical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
-
- Angélica Figueroa
- Authors' Affiliations: 1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña; 2Clinical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
-
- Rosario García-Campelo
- Authors' Affiliations: 1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña; 2Clinical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
-
- Manuel Valladares-Ayerbes
- Authors' Affiliations: 1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña; 2Clinical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
-
- Enrique Grande-Pulido
- Authors' Affiliations: 1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña; 2Clinical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
-
- Luis Antón-Aparicio
- Authors' Affiliations: 1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña; 2Clinical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
説明
<jats:title>Abstract</jats:title> <jats:p>The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. The tyrosine kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of many tumors. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma, and it is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. However, it is increasingly evident that sunitinib may display collateral effects on other proteins beyond its main target receptors, eliciting undesirable and unexpected adverse events. A better understanding of the molecular mechanisms underlying these undesirable sunitinib-associated side effects will help physicians to maximize efficacy of sunitinib and minimize adverse events. Here, we focus on new insights into molecular mechanisms that may mediate sunitinib-associated adverse events. Mol Cancer Ther; 10(12); 2215–23. ©2011 AACR.</jats:p>
収録刊行物
-
- Molecular Cancer Therapeutics
-
Molecular Cancer Therapeutics 10 (12), 2215-2223, 2011-12-01
American Association for Cancer Research (AACR)